Quantum Biopharma (NASDAQ:QNTM) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Quantum Biopharma (NASDAQ:QNTM) from a strong sell rating to a sell rating in a research note released on Saturday morning.

Separately, Weiss Ratings cut shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Quantum Biopharma Stock Up 1.8%

Quantum Biopharma stock opened at $2.89 on Friday. The company has a 50 day moving average of $4.01 and a 200-day moving average of $4.30. Quantum Biopharma has a twelve month low of $2.07 and a twelve month high of $31.91. The stock has a market capitalization of $18.50 million, a PE ratio of -0.35 and a beta of 0.43.

Institutional Investors Weigh In On Quantum Biopharma

Several institutional investors have recently bought and sold shares of QNTM. Virtu Financial LLC acquired a new position in Quantum Biopharma during the 4th quarter worth approximately $76,000. Jane Street Group LLC acquired a new stake in shares of Quantum Biopharma in the fourth quarter valued at approximately $80,000. Finally, Platform Technology Partners acquired a new stake in shares of Quantum Biopharma in the first quarter valued at approximately $199,000. Institutional investors own 1.24% of the company’s stock.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.